Summit Therapeutics Inc
SMMT
$3.55
Closing
▼-1.11%
1D
▲36.02%
YTD
Market cap
$2.49B
52 week high
$5.22
52 week low
$1.30
Volume
657,651
Check if the stock is halal
Unlock Industry-grade Shariah Compliance for global stocks. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.
We provide unparalleled value and service.
Screened by AAOIFI Certified Shariah Advisor & Auditor.
Get started from just $3.99/month
Market cap
$2.49B
Analysts' Rating
-
Price Target (Mean)
-
Total Analysts
1
P/E
Operating Margin
0.00%
Beta
-1.13
Revenue Growth (Annual)
-61.03%
52 week high
$5.22
52 week low
$1.30
Div. Yield
%
EPS Annual Growth
0.00
Note on Purification and Zakat
- Purification and Zakat (for long-term investing) calculations are in USD per share and based on AAOIFI methodology. AAOIFI requires purification every financial period (e.g. quarterly).
- If you follow S&P Shariah’s Dividend-only purification, then remove the impure income % from the dividends you receive. No purification required for non-dividend paying stocks, according to S&P Shariah.
- For Zakat, if you did not invest in a company from a long term perspective, then consider the shares as trading goods and give 2.5% of the total value if a year has passed on them.
Company Profile
Summit Therapeutics Inc. is a biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The Company is engaged in research and development activities, primarily comprising oncology product research activities (including ivonescimab), and anti-infectives program activities. Ivonescimab, is a novel, potential first-in-class bispecific antibody intending to combine the benefits of immunotherapy via a blockade of PD-1 with the anti-angiogenesis benefits of an anti-VEGF into a single molecule. The Company’s preclinical candidate, SMT-738, from the DDS-04 series for development in the fight against multi-drug resistant infections, specifically Carbapenem-resistant Enterobacteriaceae (CRE) infections. It owns a genetics platform and a suite of software-based technologies (Discuva Platform).
